The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Contract Signed with ScandiNova

22 Jul 2014 07:00

RNS Number : 9237M
Advanced Oncotherapy PLC
22 July 2014
 



22 July2014

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

 

Contract Signed with ScandiNova Systems AB

 

Advanced Oncotherapy (AIM: AVO), the developer of the next generation of particle therapy using protons to treat cancer, announces that it has entered into a collaboration with industry leader ScandiNova Systems AB ("ScandiNova"). ScandiNova will develop the high energy systems that will power the unit of the proprietary LIGHT system which will create the proton beam.

 

ScandiNova was founded in 2001 to commercialise technical expertise in pulsed power applications including Radiotherapy, Radar, industrial X-ray and scientific accelerator systems. The company is located in Uppsala, Sweden and has established a global network of collaborations with highly skilled and experienced partners covering industry, academia and research organisations such as CERN in Europe, Lawrence Livermore and Brookhaven National Laboratories in the US.

ScandiNova specialises in the development of solid state controlled power systems which require about one third of the space and are 30% more efficient than those used in standard, older technology - synchrotrons.

Mikael Lindholm, Founder, Senior VP Sales & Marketing ScandiNova, commented: "We have been working with ADAM since 2007 and from the very start have seen the potential in the LIGHT technology which should deliver a superior proton therapy technology. Our Solid State Pulse Power products are widely used and are now installed in 28 different countries in Europe, Asia, Australia, and North and South America. For us, it is a privilege to be working with an organisation which could become the number one supplier of the next generation of proton therapy. "

 

Sanjeev Pandya, CEO of Avdanced Oncotherapy, added: "In our due diligence prior to the acquisition of the LIGHT technology, it became clear that there were already many world class partners involved in the development of the LIGHT programme. ScandiNova is one such partner and I am really pleased to be able to make this announcement. Advanced Oncotherapy is going to continue this relationship and ScandiNova will become a key partner and supplier in helping us develop our complete LIGHT system."

 

For further information contact:

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya (CEO)

Tel: +44 20 3617 8739

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten

 

Beaufort Securities (Joint Broker)

 

Tel: +44 20 7382 8300

Saif Janjua / Jon Levinson

 

 

Walbrook PR (Financial PR & IR)

avo@walbrookpr.com

Anna Dunphy / Mike Wort

 

Tel: +44 20 7933 8780

 

About Advanced Oncotherapy Plc

 

Mission:

To facilitate the wider use of particle therapy with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider.

 

Key corporate messages:

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This LIGHT system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

AVO is a provider of proton radiotherapy that harnesses the best in modern technology. As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

 

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

For more information, please visit http://www.avoplc.com

 

About ScandiNova

 

ScandiNova Systems AB is a company based in Uppsala, Sweden. The company has an office in USA and representatives in 8 other countries. The company is growing continuously, since many customers in various applications are leaving the old traditional technology.

 

ScandiNova provides advanced high power Pulse Generators and fully integrated RF units, providing RF power up to 100MW and voltage pulses up to 500kV. The ScandiNova products are based on a unique patented Solid State parallel switching technology, which provides very high reliability and exceptional pulse quality and precision. Additionally, the power consumption is about 30% less than the traditional technology, which in high power applications is an important environmental requirement.

 

ScandiNova is supported by its main strong owners SEB Ventures (part of the biggest Swedish Bank SEB) and Industrifonden (the biggest government initiated fund).

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTVFLFLZDFFBBQ
Date   Source Headline
25th Apr 20139:34 amRNSDirector Dealing
24th Apr 20137:00 amRNSIssue of Equity
24th Apr 20137:00 amRNSProposed Acquisition of ADAM S.A, a CERN Spin Off
22nd Apr 20137:00 amRNSFirst UK Customers for IORT Treatment
11th Apr 20134:48 pmRNSCollaboration Announcement
11th Apr 20134:44 pmRNSCollaboration Announcement
8th Apr 20137:00 amRNSAppointment of Director
18th Mar 20137:00 amRNSDirectorate Change
18th Feb 20137:00 amRNSPotential Acquisition
15th Jan 201312:17 pmRNSDisposal
21st Dec 20123:54 pmRNSResult of EGM
5th Dec 20126:10 pmRNSSale of subsidiary, Notice of Meeting
5th Nov 20127:00 amRNSPlacing to raise £0.35 million with AB Segulah
28th Sep 201211:55 amRNSHalf Yearly Report
20th Sep 20123:21 pmRNSIssue of Equity
7th Sep 20121:33 pmRNSChange of Name
31st Aug 20121:03 pmRNSResult of GM
8th Aug 20123:15 pmRNSNotice of AGM
1st Aug 20127:00 amRNSIssue of Equity
16th Jul 20127:00 amRNSProposed Demerger
5th Jul 20123:26 pmRNSIssue of Equity
29th Jun 20121:16 pmRNSFinal Results
28th Jun 20127:00 amRNSAppointment of Director
12th Jun 20127:00 amRNSAgreement with Varigen Technologies
11th Jun 20122:24 pmRNSHolding(s) in Company
8th Jun 201212:48 pmRNSHolding(s) in Company
8th Jun 20127:00 amRNSMarketing & Business Development Appointment
18th May 20125:26 pmRNSIssue of Equity
3rd May 20123:45 pmRNSHolding(s) in Company
3rd May 20123:45 pmRNSHolding(s) in Company
20th Apr 20121:03 pmRNSChange of Registered Office
19th Apr 20127:00 amRNSFolkestone Women's Health Project
28th Mar 20127:00 amRNSRestructuring, Proposed Change of Name, etc
26th Mar 20126:05 pmRNSHolding(s) in Company
22nd Mar 201210:59 amRNSHolding(s) in Company
13th Mar 20127:05 amRNSOncotherapy Resources Limited
28th Feb 20122:23 pmRNSAdmission Date and Total Voting Rights
27th Feb 20127:00 amRNSPlacing and Directors' Shareholdings
14th Feb 20127:00 amRNSCompletion of Medical Centre Development
31st Jan 20123:24 pmRNSResult of AGM
31st Jan 20127:00 amRNSAGM Trading Update
16th Jan 20124:34 pmRNSHolding in Company
21st Dec 20111:00 pmRNSRestoration - CareCapital Group plc
21st Dec 201112:36 pmRNSStatement re. Suspension
21st Dec 20119:17 amRNSHalf Yearly Report
21st Dec 20119:17 amRNSFinal results & notice of AGM
16th Dec 20114:58 pmRNSDirectorate Change
19th Sep 201111:45 amRNSResult of EGM
8th Sep 20112:41 pmRNSResolution to grant plannning permission
1st Sep 20114:23 pmRNSNotice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.